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Available online 31 August 2016Microcephalic osteodysplastic primordial dwarﬁsm type 1 (MOPD1), or Taybi-Linder syndrome is characterized
bydistinctive skeletal dysplasia, severe intrauterine and postnatal growth retardation,microcephaly, dysmorphic
features, and neurological malformations. It is an autosomal recessive disorder caused by homozygous or com-
pound heterozygous mutations in the RNU4ATAC gene resulting in impaired function of the minor spliceosome.
Here, we present the ﬁrst report on bone morphology, bone density and bone microstructure in two adult
MOPD1 patients and applied radiographs, dual energy X-ray absorptiometry, high-resolution peripheral quanti-
tative computed tomography and biochemical evaluation.
The MOPD1 patients presented with short stature, low BMI but normal macroscopic bone conﬁguration. Bone
mineral density was low. Compared to Danish reference data, total bone area, cortical bone area, cortical thick-
ness, total bone density, cortical bone density, trabecular bone density and trabecular bone volumeper tissue vol-
ume (BV/TV) were all low. These ﬁndingsmay correlate to the short stature and low body weight of the MOPD1
patients. Our ﬁndings suggest that minor spliceosome malfunction may be associated with altered bone
modelling.








Microcephalic Osteodysplastic Primordial Dwarﬁsm type I
(MODP1), or Taybi-Linder syndrome [1,2], presents with distinctive
skeletal dysplasia, severe intrauterine and postnatal growth retardation,
microcephaly, central nervous system abnormalities, cataract, facial
dysmorphism, sparse thin hair and dry skin [3]. MOPD1 is caused by
biallelic mutations in the RNU4ATAC gene encoding the small nuclear
RNA (snRNA) U4atac. The patients often die in early childhood. At pres-
ent, approximately 42 children with MOPD1 and ten different
RNU4ATAC mutations have been reported [4]. Radiological ﬁndings in
infants with MOPD1 include dysplasia of the osseous skeleton with
cleft vertebral arches, horizontal acetabula and short and bowed long
bones [5]. However, the MOPD1 phenotype of adults, including bone
phenotype, is previously unreported.dense University Hospital, Sdr.
rd).
. This is an open access article underTwo splicing mechanisms are present in eukaryotic cells. While the
majority of introns, U2-type introns, are removed by the major
spliceosome, the human genome contains around 800 U12-type in-
trons, spliced by the slower minor spliceosome [6]. The U12 introns
are found in 563 genes, typically containing only a single U12-type in-
tron, surrounded by U2-type introns [7] and the resulting gene products
are involved in a broad variety of cellular functions as they are found, ac-
cording to the U12 Intron Database [8].
The pathophysiological background of MOPD1 is impaired function
of the minor spliceosome as the RNU4ATAC gene encodes the snRNA
U4atac, one of ﬁve snRNAs constituting the minor spliceosome [9].
Functional assays show thatmutations in RNU4ATAC reduceU12 depen-
dent splicing activity by N90% [10].
In our clinic, two adult siblings were diagnosed with MOPD1. Their
short height prompted us to study the bone morphology and
microarchitecture in this rare condition in order to explore the role of
minor spliceosome function in relation to bone structure. We applied
dual energy X-ray absorptiometry (DXA) scans and high-resolution pe-
ripheral quantitative computed tomography (HR-QCT) and identiﬁed
abnormal bone microstructure. Biochemical analyses were performed
in order to exclude common conditions affecting bone metabolism.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Clinical ﬁndings.
Female patient Male patient Mother Father
Gender F M F M
Age (years) 24 17 46 50
Height (cm) 142 143 169 180
Weight (kg) 37.6 33.0 69.8 66.0
BMI (kg/m2) 18.3 16.1 24.1 20.3
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2.1. Patient material
The two siblings, age 17 and 24 years, diagnosed with MOPD1 are
the second and third child of healthy non-consanguineous Caucasian
parents with an otherwise unremarkable family history. The family in-
cludes a 29 year old, unaffected sister. Both patients presented with
pre- and postnatal growth retardation (-4SD), microcephaly, develop-
mental delay, cataract, hearing loss and dysmorphic features and they
did not report of any previous fractures. The siblings are the ﬁrst sub-
jects with MOPD1 reported to have survived into adult life [11].
The study was approved by The Ethic Committee, Region of South-
ern Denmark (Project ID: S-20130058) and participants gave signed in-
formed consent.
2.2. Mutation analysis
Genomic DNA from the patients and the parents were analysed at
the Institute of Genetics &Molecular Medicine, University of Edinburgh,
UK [11]. The RNU4ATAC gene was screened by bidirectional Sanger se-
quencing and analyses were performed using Mutation Surveyor
(Softgenetics Inc.). The ﬁndings were validated by bidirectional Sanger
sequencing at the Department of Clinical Genetics, Odense University
Hospital, using SeqMan Pro v.12.0, DNA Star.
2.3. Bone parameters and body composition
Radiographs of radius, ulna, tibia and ﬁbula, and proximal femur
were obtained in two projections. Areal bone mineral density (aBMD)
was measured at the lumbar spine (L1–L4), total hip and the femoral
neck using DXA (Hologic Discovery, Waltham, Massachusetts, USA). Z-
scores and T-scores were calculated using the reference range provided
by themanufacturer and the Third National Health and Nutrition Exam-
ination Survey reference [12]. Body fat per cents were evaluated by
whole body scans.
A HR-pQCT system (XtremeCT, Scanco Medical AG, Brüttisellen,
Switzerland) was used to assess bone geometry, volumetric bone
mineral density (vBMD) and microarchitecture of the non-dominant
distal radius and tibia. Measures of total, cortical and trabecular
microarchitecturewere computed using the standardmanufacture soft-
ware [13]. Standardized algorithmswere used to separate the bone into
cortical and trabecular compartments, calculate trabecular bone volume
per tissue volume (BV/TV), trabecular number (Tb.N), trabecular thick-
ness (Tb.Th), and trabecular spacing (Tb.Sp) as previously described
[14]. Lastly, images were used as input in a ﬁnite element analysis
(FEA) using software provided by the manufacturer (μFE element anal-
ysis solver v.1.15, Scanco Medical, Brüttisellen, Switzerland) in order to
estimate bone strength [15]. The manufacturer phantom was scanned
daily for quality control (QRM, Möhrendorf, Germany).
2.4. Biochemical evaluation
Blood samples were collected at 8 am (not fasting) and biochemical
evaluation, including measurements of bone turnover markers
Procollagen Type 1 N-Terminal Propeptide. (PNP1) and collagen type
1 cross-linked C-telopeptide (CTX), was performed with automated
techniques in an accredited laboratory including use of liquid chroma-
tography-mass spectrometry (LC-MS) technique, Architect c16000 (Ab-
bott Diagnostics) and Cobas 4800 (Roche Molecular Diagnostics).
2.5. Candidate genes with U12 dependent splicing activity
Phenolyzer (http://phenolyzer.usc.edu/) and Phevor [16] software
were applied to search for disease associated candidate genes among
the 563 genes predicted to be affected by malfunction of the minorspliceosome. The software tools use phenotype terms to weight genes
by the chance of being associatedwith the speciﬁed phenotype. The fol-
lowing terms were used for input: postnatal growth retardation;
growth retardation; dwarﬁsm; dwarﬁsmmicrocephalic osteodysplastic
primordial dwarﬁsm; microcephaly; intrauterine growth retardation;
skeletal dysplasias; short stature; insulin like growth factor I deﬁciency
(IGF-1).
3. Results
TheMOPD1 patients were shown to be compound heterozygous for
a n.40C N T nucleotide substitution and a 85 base tandem duplication
(n.17_101dup) in RNU4ATAC (NR_023343.1) which results in an inser-
tion of a 85 base pair long sequence in position n.101. The n.40C N Tmu-
tation is extremely rare in the background population (ExAC minor
allele frequency b 1 × 10−4) and predicted to disrupt the 5′ stem I
loop of the snRNA U4atac as the n.40C is one of four bases stabilizing
this essential loop [11]. The other mutation, a novel 85 base pair inser-
tion in position n.101, is also predicted to have a major impact on con-
formation by destroying the 3′ stem I loop (in silico predictions made
by Protein Data Bank 3SIU and PyMol v.1.7 software). The parents
were each heterozygous carriers for one of these mutations conﬁrming
a cis-conﬁguration of the mutations in the patients. The father was car-
rier of the 85 base pair long tandemduplication at n.101 and themother
was carrier of the n.40C N T mutation.
The two cases with MOPD1, female and male, age 24 and 17 years,
respectively, presented with short stature of 142 and 143 cm and
body mass index of 18.3 and 16.1 (kg/m2), for the female and male pa-
tient, respectively (Table 1). The MOPD1 patients had fat percent of
36.3% and 20.8% and a lean body mass of 23.07 kg and 25.92 kg for the
female andmale patient, respectively. The height andweight of the par-
ents were within the normal range.
Radiographs of radius, ulna, femur and tibia showed normal bone
morphology including normal metaphyses (Supplementary Figs. 1–4).
Results of the bone DXA scans are summarized in Table 2. The MOPD1
patients had low total bone mineral density, and Z-scores varied be-
tween −2.0 and −3.3 SD and −3.3 and −3.7 SD in the female and
male patient, respectively. The father, age 50, also had a low bone min-
eral density with T-scores of−2.0 SD in the lumbar spine,−2.8 SD in
the femoral neck and−2.4 in the hip. The mother, age 46, had normal
bonemineral density. HR-pQCT results from scans of radius and tibia re-
vealed that both MOPD1 patients had low values of cortical bone area,
cortical thickness, total bone density, cortical bone density, trabecular
bone density and trabecular bone volume per tissue volume (BV/TV)
compared to age- and gender matched normal material [17,18] (Table
3). Estimated bone strength in both tibia and radius showed signiﬁcant-
ly lower failure load in cases compared to age- and sexmatched normal
values. For the female MOPD1 patient the estimated failure load in radi-
us and tibia were 2377 and 5166 N compared to a mean of 3993 and
10,923 N, respectively, in the normal population [17]. For the male
MOPD1 patient, the estimated failure load in radius and tibia were
1879 and 6307N compared to amean of 3009N and 7957N, respective-
ly, in the normal population [18].
Biochemical evaluations are shown in Table 4. Normal levels of para-
thyroid hormone and thyroid stimulating hormone were seen in all
familymembers. Themale patient had a high level of follicle stimulating
Table 2
Bone area, bone mineral content, bone density, Z- and T-scores evaluated by DXA in






Lumbar spine (L1–L4), total area
(cm2)
44.07 47.64 63.55 72.51
Lumbar spine (L1–L4), total BMC
(g)
35.87 31.18 61.09 62.98
Lumbar spine (L1–L4), total BMD
(g/cm2)
0.814 0.655 0.961 0.869
Lumbar spine (L1–L4), total BMD
(T-score) SD
−2.1 −4.0 −0.8 −2.0
Lumbar spine (L1–L4), total BMD
(Z-score) SD
−2.0 −3.7 −0.3 −1.7
Femur neck, area (cm2) 4.53 4.86 4.95 6.03
Femur neck, total BMC (g) 2.19 2.58 3.81 3.34
Femur neck, total BMD (g/cm2) 0.482 0.530 0.769 0.554
Femur neck, total BMD (T-score) SD −3.3 −2.9 −0.7 −2.8
Femur neck, total BMD (Z-score) SD −3.3 −3.4 −0.2 −2.0
Hip, total area (cm2) 31.65 33.20 35.86 46.54
Hip, total BMC (g) 18.63 19.95 32.95 31.21
Hip, total BMD (g/cm2) 0.589 0.601 0.919 0.671
Hip, total BMD (T-score) SD −2.9 −2.9 −0.2 −2.4
Hip, total BMD (Z-score) SD −2.9 −3.3 0.1 −2.1
Whole body scan, total BMC (g) 1301.34 1137.91 2232.78 3039.76
Whole body scan, total BMD
(g/cm2)
0.901 0.825 1.081 1.364
Whole body scan, lean body mass
(g)
23,073.5 25,922.2 45,371.4 54,144.2
Whole body scan, % fat (%) 36.3 20.8 33.1 15.5
BMC: bone mineral content. BMD: bone mineral density.
Table 3
Geometry, volumetric bone mineral density, microarchitecture, estimated bone strength







Total bone area (mm2) 267.9 252.8 295.6 460.9
Cortical bone area (mm2) 30.0 15.4 57.1 63.8
Cortical thickness (mm) 0.53 0.47 0.82 0.76
Total bone density (mg/cm3) 194.4 174.1 283.1 237.3
Cortical bone density (mg/cm3) 796.8 599.3 920.6 821.9
Trabecular bone density
(mg/cm3)
103.3 116.0 129.1 137.7
Trabecular BV/TV (%) 8.6 9.6 10.7 11.4
Trabecular bone area (mm2) 231.5 222.4 235.5 390.0
Trabecular number (mm−1) 1.71 1.81 1.91 1.71
Trabecular thickness (mm) 0.050 0.053 0.056 0.066
Trabecular spacing (mm) 0.533 0.497 0.467 0.515
Cortical porosity (%) 0.26 1.77 0.78 2.25
Stiffness (kN/mm) 46.4 35.6 71.9 96.1
FEA failure load (N) 2377 1879 3738 4855
Tibia
Total bone area (mm2) 595.6 610.4 708.3 1048.5
Cortical bone area (mm2) 60.8 78.9 112.6 101.0
Cortical thickness (mm) 0.68 0.95 1.06 0.92
Total bone density (mg/cm3) 178.9 184.8 310.6 169.6
Cortical bone density (mg/cm3) 856.7 803.0 914.2 784.5
Trabecular bone density
(mg/cm3)
97.3 84.0 200.1 96.4
Trabecular BV/TV (%) 8.1 7.0 16.6 8.0
Trabecular bone area (mm2) 531.5 527.9 593.3 937.9
Trabecular number (mm−1) 1.89 1.26 2.25 1.43
Trabecular thickness (mm) 0.042 0.055 0.074 0.056
Trabecular spacing (mm) 0.484 0.743 0.369 0.641
Cortical porosity (%) 0.82 0.59 2.71 7.55
Stiffness (kN/mm) 97.8 122.3 210.8 177.2
FEA failure load (N) 5166 6307 10,650 9165
BV/TV: bone volume per tissue volume. FEA: ﬁnite element analysis. N: Newton.
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tosterone. Both MOPD1 patients had very low levels of IGF-1 with
values of 39 μg/L and 78 μg/L in the female andmale patient, respective-
ly. Normal levels of IGF-1 were observed in both patients in childhood.
High levels of the bone turnover markers, with a serum type 1
procollagen (P1NP) of 352 μg/L (normal range 15–80 μg/L) and
carboxy-terminal collagen crosslinks (CTX) of 1.08 μg/L (normal range
0.17–0.6 μg/L) [19] were seen in the male patient.
Result of search for MOPD1-associated gene products among the
563 genes containing U12-type introns can be found in Supplementary
Table 1. Some genes, exempliﬁed by the OCRL gene, associated
with Lowe Syndrome [20], the MATN3 gene, involved in
spondyloepimetaphyseal dysplasia [21] and BRAF and RAF1 associated
with Leopard Syndrome [22] contain U12-type introns and are known
to be involved in bone metabolism or growth retardation.
4. Discussion
To the best of our knowledge, this represents the ﬁrst clinical de-
scription of bone morphology and structure in adult subjects with
MOPD1. Radiographs showed normal macroscopic bone conﬁguration
while infant MOPD1 patients typically present with macroscopic skele-
tal dysplasia [23]. However, DXA scans showed that both MOPD1 pa-
tients had low bone mass. For both MOPD1 patients, the HR-pQCT
parameters were substantially lower compared to the population
based normal bone parameters of young adults [17,18].
The biochemical evaluation established that the low bone mass in
the two MOPD1 patients result from neither vitamin D deﬁciency nor
hyperthyroidism. However, we did observe low levels of IGF-1 in both
patients. The patients declined formal testing of growth hormone deﬁ-
ciency in adulthood and treatment with GH was not initiated. Low
level of IGF-1 may result from a low level of growth hormone (GH)
but several factors such as the nutritional status is known to affect the
IGF-1 level [24]. Although the body weight of both cases was low,
therewas no suspicion ofmalnutrition. GH and IGF-1 are themain stim-
ulators of longitudinal bone growth and are also important for the ac-
quisition of bone mass during the pre-pubertal period [25].
Importantly, normal levels of IGF-1 were observed in both patients in
childhood (measured at age 1 and 10 years for the female patient and
at age 1 year for themale patient compared to age- and gendermatched
normal material [26]). Though low levels of IGF-1 was observed in the
adult patients this may not be a hallmark of the MOPD1 phenotype
and is most likely not alone causative of the growth restriction. The
male patient presented with high levels of P1NP and CTX, indicating
high bone turnover. This is however, frequently observed in males
younger than 25 years, [19] most likely indicating that bone growth
may not have been ﬁnalized rather than abnormal bone metabolism.
FSH was above the normal range in the male case, but the testosterone
level was above normal ruling out hypogonadism as the cause of low
bone mass. Regrettably, reassessments of gonadotropins were not
performed.
Ourﬁndingsmay suggest thatmalfunction of theminor spliceosome
could affect bone growth, accrual of bone mineral density in childhood
causing lower peak bone mass and possibly even bone metabolism in
adulthood. However, osteoporosis has also been described in patients
with achondroplasia [27], the most common form of human dwarﬁsm.
In addition, factors like weight, height, age and physical activity highly
inﬂuence bone strength [28]. The MOPD1 patients have a low body
weight and relatively low level of physical activity. The relatively high
fat percent, compared to age- and gender matched normal material
[29] and the lowmuscle mass found in theMOPD1 patients most likely,
at least to some extent, result from physical inactivity.
The fact that the father had low bone mass [30] entails that the ab-
normal DXA scan results in the siblings cannot unequivocally be con-
cluded to result from altered expression of gene products spliced by
the minor spliceosome as the siblings may be genetically predisposed
Table 4
Biochemical evaluation of MOPD1 cases and family members.
Female patient Male patient Mother Father
P1NP (15–80 μg/L) 63 μg/L 352 μg/L* 40 μg/L 28 μg/L
CTX (0.17–0.6 μg/L) 0.41 μg/L 1.08 μg/L* 0.30 μg/L 0.26 μg/L
25-OH Vitamin D (50–160 nmol/L) 63 nmol/L 177 nmol/L* Na Na
PTH (1.1–6.9 pmol/L) 2.8 pmol/L 5.2 pmol/L 3.7 pmol/L 3.8 pmol/L
TSH (0.5–4.3 10−3 IU/L) 3.9·10−3 IU/L 4.1·10−3 IU/L 1.2 10−3 U/L 1.0·10−3 U/L
Thyroxine (T4) (60–130 nmol/L) Na 87 nmol/L Na Na
FSH (1.1–7.9 IU/L) 5.2 IU/L 21 IU/L Na Na
LH (1.5–11 IU/L) 2.4 IU/L 8.0 IU/L Na Na
Prolactin (2–14 μg/L) 10 μg/L 7 μg/L Na Na
Estradiol (0.24–2.4 nmol/L) 0.31 nmol/L Na Na Na
Testosterone (8.40–30.0 nmol/L) Na 30.8 nmol/L* Na Na
Prolactin (2–14 μg/L) 10 μg/L 7 μg/L Na Na
Cortisol (200–700 nmol/L) 238 nmol/L 266 nmol/L Na Na
Corticotrophin (ACTH) (2–14 pmol/L) 3 pmol/L 5 pmol/L Na Na
IGF-1 (females age 20–29, 188 μg/L [37]; males age 15–18 years, 135–835 μg/L) 39 μg/L* 78 μg/L* Na Na
P1NP: procollagen type 1N-terminal propeptide. CTX: C-terminal cross-linking telopeptide of type I collagen. PTH: parathyroid hormone. TSH: thyroid stimulatinghormone. T4: thyroxine.
FSH: follicle stimulating hormone. LH: luteinizing hormone. IGF-1: insulin-like growth factor 1. Na: not evaluated. * depicts an abnormal value.
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tantly, secondary causes of low bone mass were not observed in the
father, suggesting that cases may be genetically predisposed to
osteoporosis as well.
A weakness of the study is that measures of parameters including
lean body mass, bone cortical structure and bone mineral density are
confounded by the short stature of the patients. The low lean body
mass may, for example actually be appropriate according to the low
height of the patients. In addition to the challenges of interpretation of
results, evaluations of patients that differ from the reference material
also entail challenges on the technical side. The DXA scan technique is
based on two dimensional images and systematically underestimates
bonemineral density of smaller bones [33], confounding the bone min-
eral density measurements made on the MOPD1 patients. For the HR-
pQCT measurements, the use of the standard method with measure-
ments at a ﬁxed distance from the distal endplate of tibia and radius,
places the scan region further from the end plate in percentage of the
entire bone length in the MOPD1 patients compared to the parents,
which introduces a bias to the results. The use of a relative offset dis-
tance may have reduced this bias, however, the small body proportion
would almost certainly inﬂuence the investigations irrespective of the
method used to assess bone microarchitecture by HR-pQCT [34]. Iliac
crest bone biopsies would have provided information on bone structure
and metabolism, but neither of the cases consented to the procedures.
The two patients are compound heterozygous for two mutations in
the RNU4ATAC gene, which encodes the snRNA U4atac, one of ﬁve
snRNAs constituting the minor spliceosome. The mutations are posi-
tioned in the stem I loop of U4atac, which has been reported for other
MOPD1 patients [11]. Both mutations are predicted to have a major
functional impact on the snRNA. Thus, in the compound heterozygous
state, minor spliceosome function is predicted to be impaired.
Increasing evidence suggests that malfunction of the minor
spliceosome is causative of several recessive genetic disorders. Recently,
compound heterozygote mutations in RNU4ATAC, although distinctive
genomic positions from the MOPD1 related, have been shown to
cause Roifman Syndrome, a rare congenital disorder characterized by
pre- and postnatal growth retardation, antibody deﬁciency, skeletal ab-
normalities, retinal dystrophy, cognitive delay and dysmorphic features,
which is phenotypically different than MOPD1 even though the genetic
background is strikingly similar [35]. Most MOPD1 causal variants clus-
ter in the stem I loop of U4atac snRNA, as is the case with our patients,
while variants in the stem II seem to be speciﬁc to Roifman Syndrome
indicating a genotype-phenotype association [35]. Thus, the exact geno-
mic positions within the RNU4ATACmost likely inﬂuence to what ex-
tend transcription is affected. Biallelic mutations in the RNPC3 gene,
another gene encoding a protein involved in minor spliceosome func-
tion, was recently reported as a novel mechanism for isolated familialGH hormone deﬁciency [36], thus entailing more limited phenotypic
consequences.
Thus, the exact genomic positions within the RNU4ATACmost likely
inﬂuence to what extend transcription is affected. Biallelic mutations in
the RNPC3 gene, another gene encoding a protein involved in minor
spliceosome function, was recently reported as a novel mechanism for
isolated familial growth hormone deﬁciency [36], thus entailing more
limited phenotypic consequences.
No deﬁnitive conclusions can be drawn, but genes containing U12-
type introns like OCRL, MATN3, BRAF or RAF1, where intragenic muta-
tions are known to be associated with abnormal bone metabolism or
growth retardation could be involved.
In summary, we report abnormal bone microstructure of adult
MOPD1 patients and speculate that some of the gene products from
the 563 genes containing U12-type introns are involved in bonemetab-
olismor growth of statural height.Minor spliceosome function is not yet
fully understood and functional studies are essential to elucidate the
exact genotype-phenotype relations in diseases caused by mutations
in genes involved in minor intron splicing.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2016.08.023.
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